Archive
561 articles, sorted by publication time.
The challenge for engineered bacterial therapies is not only making bacteria “work,” but also keeping them where they are supposed to stay. A scaffold made from a high-toughness hydrogel offers a new materials-based path for safety control in live bacterial therapies.
A real-world analysis of nearly 60,000 adults with type 2 diabetes extends the discussion of GLP-1 drugs from weight and blood glucose to bone; the signal is intriguing, but it cannot yet be read as a bone-protecting prescription.
A cell biology study indicates that malaria parasites rely on the ARK1 protein to organize chromosome segregation; if this mechanism, which differs from that in human cells, can be precisely disrupted, it may one day weaken malaria from both the reproduction and transmission ends.
Strawberry research shows that fine-tuning the activity of a tRNA-related gene may increase color, aroma, and phytochemical content without sacrificing plant growth, fruit size, or sweetness; this opens a new, potentially lower-cost path for improving crop quality.
A routine experiment testing a single-cell sequencing workflow unexpectedly revealed a distinctive way of reading the code in a ciliate; it reminds scientists that the shared language of life is far more flexible than the textbook version suggests.
A rare progeria syndrome pushes DNA methylation from an “aging scale” into a more difficult position: it may not merely be a trace left by time, but a biological force that can disrupt stem cells, bone, and metabolism.
An animal study shows that the small molecule OLE, produced through the PM20D1 pathway, can alter the state of microglia, reduce amyloid plaques, and improve memory performance; it remains far from clinical treatment, but adds a concrete clue to immunomodulatory strategies for Alzheimer’s disease.
A study from Scripps Research suggests that the difficulty of shutting down immune responses in the brain in Alzheimer’s disease may be linked to chemical modifications of the STING protein; the finding offers new clues for anti-inflammatory treatment, while also reminding us that clinical application remains some distance away.
A Nature Immunology study rewrites the role of MHC I in anticancer immunity: when cancer cells lose this identity card, they may not only evade killer T cells, but also become exposed to ferroptosis pressure triggered by helper T cells.
SLAMF6 may cause cancer-fighting T cells to gradually burn out on the battlefield; blocking this self-activating molecular signal offers a new drug target for extending the immune attack, but clinical proof remains some distance away.
Isomorphic Labs says its AI drug design pipeline is moving toward first-in-human trials; the real question is no longer only whether models can design molecules, but whether these candidates can pass through the narrow gate of clinical testing, safety, and regulation.
A Cell study links part of Alzheimer’s disease risk to cancer-driving mutations that accumulate in aging blood cells; this does not mean dementia is cancer, but it does prompt scientists to re-examine the channels between blood, brain immunity, and chronic inflammation.